Cargando…
A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet
Many commercially available wound products focus on improving one stage of the wound healing cascade. While this targeted approach works for specific wounds, there is a need for products that can reliably and comprehensively progress a wound through multiple stages. This preliminary in vitro study w...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503338/ https://www.ncbi.nlm.nih.gov/pubmed/36142583 http://dx.doi.org/10.3390/ijms231810670 |
_version_ | 1784795938256060416 |
---|---|
author | Rodriguez, Isaac Conti, Tricia Bionda, Nina |
author_facet | Rodriguez, Isaac Conti, Tricia Bionda, Nina |
author_sort | Rodriguez, Isaac |
collection | PubMed |
description | Many commercially available wound products focus on improving one stage of the wound healing cascade. While this targeted approach works for specific wounds, there is a need for products that can reliably and comprehensively progress a wound through multiple stages. This preliminary in vitro study was performed to directly compare the inflammatory reduction and growth factor production effects of three commercially available wound care products: a collagen sheet (COL), a Manuka Honey Calcium Alginate sheet (MH), and a novel bioengineered sheet comprised of a collagen derivative (gelatin), Manuka honey, and hydroxyapatite (BCMH). Macrophages and human dermal fibroblasts were directly seeded on all three commercial products, and supernatants were analyzed for inflammatory markers and growth factors, respectively. Comparing the MMP-9/TIMP-1 ratio, BCMH resulted in 11× lower levels of this inflammation biomarker compared to COL, and 3× lower levels compared to MH. Both the COL and BCMH products created an environment conducive to expression and release of relevant growth factors, while the MH product showed the lowest levels of growth factor expression of all three commercially available products tested. The favorable 11× lower MMP-9/TIMP-1 ratio observed with the BCMH product compared to the COL product suggests that the BCMH products provided a superior comprehensive approach to healthy progression of the wounds by providing an additional benefit of reducing the inflammatory response in vitro. |
format | Online Article Text |
id | pubmed-9503338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95033382022-09-24 A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet Rodriguez, Isaac Conti, Tricia Bionda, Nina Int J Mol Sci Communication Many commercially available wound products focus on improving one stage of the wound healing cascade. While this targeted approach works for specific wounds, there is a need for products that can reliably and comprehensively progress a wound through multiple stages. This preliminary in vitro study was performed to directly compare the inflammatory reduction and growth factor production effects of three commercially available wound care products: a collagen sheet (COL), a Manuka Honey Calcium Alginate sheet (MH), and a novel bioengineered sheet comprised of a collagen derivative (gelatin), Manuka honey, and hydroxyapatite (BCMH). Macrophages and human dermal fibroblasts were directly seeded on all three commercial products, and supernatants were analyzed for inflammatory markers and growth factors, respectively. Comparing the MMP-9/TIMP-1 ratio, BCMH resulted in 11× lower levels of this inflammation biomarker compared to COL, and 3× lower levels compared to MH. Both the COL and BCMH products created an environment conducive to expression and release of relevant growth factors, while the MH product showed the lowest levels of growth factor expression of all three commercially available products tested. The favorable 11× lower MMP-9/TIMP-1 ratio observed with the BCMH product compared to the COL product suggests that the BCMH products provided a superior comprehensive approach to healthy progression of the wounds by providing an additional benefit of reducing the inflammatory response in vitro. MDPI 2022-09-14 /pmc/articles/PMC9503338/ /pubmed/36142583 http://dx.doi.org/10.3390/ijms231810670 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Rodriguez, Isaac Conti, Tricia Bionda, Nina A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet |
title | A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet |
title_full | A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet |
title_fullStr | A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet |
title_full_unstemmed | A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet |
title_short | A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet |
title_sort | preliminary direct comparison of the inflammatory reduction and growth factor production capabilities of three commercially available wound products: collagen sheet, manuka honey sheet, and a novel bioengineered collagen derivative + manuka honey + hydroxyapatite sheet |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503338/ https://www.ncbi.nlm.nih.gov/pubmed/36142583 http://dx.doi.org/10.3390/ijms231810670 |
work_keys_str_mv | AT rodriguezisaac apreliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet AT contitricia apreliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet AT biondanina apreliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet AT rodriguezisaac preliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet AT contitricia preliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet AT biondanina preliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet |